The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
[EN] NUCLEAR RECEPTOR BINDING AGENTS<br/>[FR] AGENTS DE LIAISON À DES RÉCEPTEURS NUCLÉAIRES
申请人:GTX INC
公开号:WO2008130571A1
公开(公告)日:2008-10-30
[EN] The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity. [FR] La présente invention concerne une nouvelle classe de modulateurs sélectifs des récepteurs des strogènes (MSRO). Les composés MSRO peuvent être utilisés dans la prévention et/ou le traitement d'une variété de maladies et affections comprenant des cancers tels que les cancers de la prostate et du sein, l'ostéoporose, les troubles hormonaux, les bouffées de chaleur et les symptômes vasomoteurs, les troubles neurologiques, les maladies cardiovasculaires et l'obésité.